Frontlight ResearchEarly access
What researchers published on Neuromyelitis optica (NMOSD)
4,494 papers, newest first.
Showing 20 of 61
Randomised trialAstrocytic and Axonal Injury Biomarkers in AQP4 Antibody-Positive NMOSD: Insights From PREVENT and CHAMPION-NMOSD.Neurology(R) neuroimmunology & neuroinflammation
In plain wordsRead moreRead the paper on PubMedRandomised trialObinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial.Nature medicine
In plain wordsRead moreRead the paper on PubMedRandomised trialLong-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results.Neurology(R) neuroimmunology & neuroinflammation
In plain wordsRead moreRead the paper on PubMedRandomised trialEfficacy of Inebilizumab in N-MOmentum Trial Participants With or Without Prior Immunosuppressants.Annals of clinical and translational neurology
In plain wordsRead moreRead the paper on PubMedRandomised trialA novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial.Frontiers in immunology
In plain wordsRead moreRead the paper on PubMedTrial resultSafety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.Multiple sclerosis (Houndmills, Basingstoke, England)
In plain wordsRead moreRead the paper on PubMedRandomised trialPrognostic Modeling for the Failure of Intravenous Methylprednisolone and the Risk of Visual Disability in AQP4-IgG Positive NMOSD-ON.Translational vision science & technology
In plain wordsRead moreRead the paper on PubMedRandomised trialLong-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.Neurology(R) neuroimmunology & neuroinflammation
Trial resultACT with NMOSD: A targeted, telehealth-delivered mental health intervention for patients & caregivers.Multiple sclerosis and related disorders
Trial resultAnalysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data.Multiple sclerosis and related disorders
Trial resultFirst-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders.CNS neuroscience & therapeutics
Randomised trialB cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity.Annals of clinical and translational neurology
Randomised trialSafety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.The Lancet. Neurology
Trial resultEfficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study.Immunological medicine
Randomised trialEfficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.Multiple sclerosis and related disorders
Randomised trialAttack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.Multiple sclerosis (Houndmills, Basingstoke, England)
Randomised trialSerum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.Journal of neurology, neurosurgery, and psychiatry
Randomised trialLong-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.Neurology(R) neuroimmunology & neuroinflammation
Trial resultAnti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.Signal transduction and targeted therapy
Randomised trialAssociation between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.EBioMedicine